Clinical trials: LUTS(Lower Urinary Tract Symptoms)
Prostatic Hyperplasia
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate.
- Trial name
- NCT00457457
- Testing
- Tamsulosin, UK-369,003
- Where
- 46 sites in Australia, Belgium and 13 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
LUTS, Benign Prostatic Hyperplasia
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02180997
- Testing
- Tamsulosin, Solifenacin, Tamsulosin and solifenacin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device.
- Trial name
- Omega (NCT05757687)
- Testing
- Omega device
- Where
- 5 sites in Georgia
- Volunteers
- 11 people
- Sponsor
- ProArc Medical
Benign Prostatic Hyperplasia
A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker.
- Trial name
- NCT02431754
- Testing
- Tadalafil, Alpha1 Blocker
- Where
- 9 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Eli Lilly and Company
Lower Urinary Tract Symptoms
Study to Evaluate Efficacy and Safety of NDS-446 in Men With Lower Urinary Tract Symptoms (LUTS)
Prospective, Randomized, Double-Blind, Placebo Controlled clinical trial to study the efficacy and the safety of NDS-446 (500 mg/cap) in Men 45 years of age or older with moderate to severe lower urinary tract symptoms (LUTS)
- Trial name
- NCT02808013
- Testing
- NDS-446
- Volunteers
- 116 people
- Sponsor
- Naturex-Dbs
Benign Prostatic Hyperplasia
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device.
- Trial name
- NCT02326454
- Testing
- talaporfin sodium, Saline, Drug Activator 100 J/cm
- Where
- 41 sites in United States
- Volunteers
- 225 people
- Sponsor
- Light Sciences Oncology
Benign Prostatic Hypertrophy
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy…
- Trial name
- NCT00427219
- Testing
- Ozarelix
- Where
- 13 sites in United States
- Volunteers
- 74 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Urethral Stricture
ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
ROBUST III is a prospective, multi-center, randomized controlled adaptive sample size clinical trial to establish the safety and effectiveness for the Optilume Stricture Drug Coated Balloon (DCB).
- Trial name
- ROBUST-III (NCT03499964)
- Testing
- Optilume Drug Coated Balloon (DCB), Control Treatment
- Where
- 22 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- Urotronic Inc.
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVIDE Studies Post Exit Analysis
A study to collect data on the post-study exit incidence of secondary reintervention using alternate surgical LUTS therapy.
- Trial name
- NCT07680543
- Testing
- ProVee Urethral Expander System
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ProVerum Medical
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms
RT-310 Dose Escalation BPH Study
RT-310, a novel implant, is intended to minimally invasive treat locally the prostate gland for the management of prostate disease, while minimizing side-effects.
- Trial name
- NCT06136819
- Testing
- RT-310
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Resurge Therapeutics Inc.
BPH (Benign Prostatic Hyperplasia)
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
The purpose of this registry is to collect information on how the Zenflow Spring System works in everyday medical practice. The registry will track how the Spring System performs during the implant procedure, and at follow-up…
- Trial name
- NCT07538622
- Testing
- Zenflow Spring System
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Zenflow, Inc.
Prostate Cancer
Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
The intention of this study is to investigate how many patients with prostate cancer, planned to be treated with LHRH analogues without history of surgery or radiotherapy, are suffering from LUTS.
- Trial name
- ANALUTS (NCT02542501)
- Where
- 32 sites in Portugal, Spain
- Volunteers
- 470 people
- Sponsor
- Ipsen
Lower Urinary Tract Symptoms
Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms
1. To study the symptomatic improvement in LUTS afforded by FLOMAX® capsules, 0.4 mg daily compared to placebo, in female patients with lower urinary tract symptoms (LUTS) with a significant component of voiding symptoms 2.
- Trial name
- NCT02244281
- Testing
- tamsulosin hydrochloride
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Butterfly Pivotal Study
A prospective, multicenter, blind randomized (2:1) controlled study comparing the International Prostate Symptom Score (IPSS) of the Active arm to the IPSS of the control arm at the 3 months follow-up and active arm IPSS score…
- Trial name
- NCT05341661
- Testing
- Butterfly Prostatic Retraction Device
- Where
- 3 sites in United States
- Volunteers
- 245 people
- Sponsor
- Butterfly Medical Ltd.
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVIDE II Bridging Study
The purpose of the ProVIDE II Bridging Study is to evaluate the performance of the Generation II delivery system when deploying the ProVee expander in subjects with symptomatic urinary obstruction secondary to BPH.
- Trial name
- NCT06236802
- Testing
- ProVee device
- Where
- 8 sites in United States, Ireland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Benign Prostatic Hyperplasia (BPH)
PERmixon® in LUTS Evaluation Study (PERLES)
The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using Tamsulosine LP 0.4 mg as a reference treatment.
- Trial name
- PERLES (NCT02121613)
- Testing
- Permixon® 160 mg, Tamsulosine LP
- Where
- 58 sites in Czechia, France and 3 more
- Volunteers
- 833 people
- Sponsor
- Pierre Fabre Medicament
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Safety and Effectiveness Study of the Zenflow Spring System
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
- Trial name
- BREEZE (NCT04987138)
- Testing
- Zenflow Spring System
- Where
- 7 sites in United States
- Volunteers
- 279 people
- Sponsor
- Zenflow, Inc.